Association between the Immune Nutritional Index and Clinical Outcomes Following Percutaneous Coronary Intervention in ST-Elevation Myocardial Infarction: A Retrospective Cohort Study

Abstract

The prognosis and recovery of the patient post-percutaneous coronary intervention (PCI) procedure for myocardial infarction (MI) form a core clinical question. It is increasingly important to know the indices that can inform more effective organizational strategies in the prevention of cardiovascular adverse development among these groups of patients. The current study investigates the relationship between a novel index, Immune–Nutritional Index (INI), a product of albumin and lymphocyte, divided by neutrophils, and the incidence of a major adverse cardiovascular event (MACE) following PCI procedures. We conducted a retrospective analysis, from January 2020 to March 2024, on 367 patients with segment elevation (ST) myocardial infarction (STEMI) who were subjected to PCI at the 904th Hospital of the Joint Logistics Support Force. We computed the INI for each patient. The prediction of INI for both in-hospital and long-term MACE was discussed, and the area under the curve (AUC) was calculated. Three hundred and sixty-seven patients were categorized according to the best cutoff value of INI, and clinical characteristics were compared. Logistic and Cox regression analyses were performed to determine independent factors associated with in-hospital and long-term MACE, respectively. The Kaplan–Meier survival analysis determined patients' discharge survival outcomes. The AUC of INI for predicting in-hospital MACE in patients with STEMI was found to be 0.666, while for long-term MACE, it was found to be 0.748. A high INI was independently associated with reduced in-hospital MACE risk among patients with STEMI in multivariate logistic regression analysis (cutoff value 7.101; p < 7.101, odds ratio [OR] = 0.418, 95% confidence interval [CI]: 0.246–0.712). High INI significantly predicted long-term MACE during a follow-up period in patients with STEMI and was independently associated with it (cutoff value 9.752; p = 0.005, hazard ratio [HR] = 0.423, 95% CI: 0.232–0.770). INI is an important predictive index for MACE during hospitalization and long-term follow-up after PCI in STEMI patients.

Keywords

major adverse cardiovascular events - prevention - Immune–Nutritional Index - PCI - inflammation - acute coronary syndrome - cardiovascular disease

• References

• 1 Murray CJL, Vos T, Lozano R. et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380 (9859): 2197-2223
• 2 Zeymer U, Ludman P, Danchin N. et al; ACVC EAPCI EORP ACS STEMI investigators group of the ESC. Reperfusion therapies and in-hospital outcomes for ST-elevation myocardial infarction in Europe: the ACVC-EAPCI EORP STEMI Registry of the European Society of Cardiology. Eur Heart J 2021; 42 (44) 4536-4549
• 3 Menozzi A. An overview on STEMI. Minerva Cardiol Angiol 2018; 66 (04) 391 . Accessed October 19, 2024 at: https://www.minervamedica.it/index2.php?show=R05Y2018N04A0391
• 4 Yoon GS, Choi SH, Woo SI. et al. Neutrophil-to-lymphocyte ratio at emergency room predicts mechanical complications of ST-segment elevation myocardial infarction. J Korean Med Sci 2021; 36 (19) e131
• 5 He J, Bian X, Song C. et al. High neutrophil to lymphocyte ratio with type 2 diabetes mellitus predicts poor prognosis in patients undergoing percutaneous coronary intervention: a large-scale cohort study. Cardiovasc Diabetol 2022; 21 (01) 156
• 6 Peng Y, Xue Y, Wang J. et al. Association between neutrophil-to-albumin ratio and mortality in patients with cardiogenic shock: a retrospective cohort study. BMJ Open 2020; 10 (10) e039860
• 7 Thygesen K, Alpert JS, Jaffe AS. et al. Fourth Universal Definition of Myocardial Infarction (2018). Circulation 2018; 138: 20
• 8 Ibanez B, James S, Agewall S. et al; ESC Scientific Document Group. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2018; 39 (02) 119-177
• 9 Rampidis GP, Benetos G, Benz DC, Giannopoulos AA, Buechel RR. A guide for Gensini Score calculation. Atherosclerosis 2019; 287: 181-183
• 10 Antman EM, Cohen M, Bernink PJ. et al. The TIMI risk score for unstable angina/non-ST elevation MI: A method for prognostication and therapeutic decision making. JAMA 2000; 284 (07) 835-842
• 11 Niccoli G, Burzotta F, Galiuto L, Crea F. Myocardial no-reflow in humans. J Am Coll Cardiol 2009; 54 (04) 281-292
• 12 Thiele H, Barbato E, Barthelemy O, Bauersachs J, Bhatt DL. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J 2021; 42: 1289-1367
• 13 Marchi F, Pylypiv N, Parlanti A. et al. Systemic Immune-Inflammation Index and systemic inflammatory response index as predictors of mortality in ST-elevation myocardial infarction. J Clin Med 2024; 13 (05) 1256
• 14 Gayretli Yayla K, Yayla C, Erdol MA, Karanfil M, Ertem AG, Akcay AB. Relationship between C-reactive protein to albumin ratio and infarct-related artery patency in patients with ST-segment elevation myocardial infarction. Angiology 2022; 73 (03) 260-264
• 15 Dong G, Huang A, Liu L. Platelet-to-lymphocyte ratio and prognosis in STEMI: A meta-analysis. Eur J Clin Invest 2021; 51 (03) e13386
• 16 Cao S, Liu Y, Ye J. et al. The value of D-dimer to lymphocyte ratio in predicting clinical outcomes after percutaneous coronary intervention in ST-segment elevation myocardial infarction patients: A retrospective study. Int Immunopharmacol 2024; 128: 111556
• 17 Wang W, Li X, Ding X. et al. Lymphatic endothelial transcription factor Tbx1 promotes an immunosuppressive microenvironment to facilitate post-myocardial infarction repair. Immunity 2023; 56 (10) 2342-2357.e10
• 18 Bodí V, Sanchis J, Núñez J. et al. Post-reperfusion lymphopenia and microvascular obstruction in ST-segment elevation acute myocardial infarction. Rev Esp Cardiol 2009; 62 (10) 1109-1117
• 19 Boag SE, Das R, Shmeleva EV. et al. T lymphocytes and fractalkine contribute to myocardial ischemia/reperfusion injury in patients. J Clin Invest 2015; 125 (08) 3063-3076
• 20 Doran AC, Lipinski MJ, Oldham SN. et al. B-cell aortic homing and atheroprotection depend on Id3. Circ Res 2012; 110 (01) e1-e12
• 21 Forteza MJ, Trapero I, Hervas A. et al. Apoptosis and mobilization of lymphocytes to cardiac tissue is associated with myocardial infarction in a reperfused porcine model and infarct size in post-PCI patients. Oxid Med Cell Longev 2018; 2018 (01) 1975167
• 22 Haumer M, Amighi J, Exner M. et al. Association of neutrophils and future cardiovascular events in patients with peripheral artery disease. J Vasc Surg 2005; 41 (04) 610-617
• 23 Luo J, Thomassen JQ, Nordestgaard BG, Tybjærg-Hansen A, Frikke-Schmidt R. Neutrophil counts and cardiovascular disease. Eur Heart J 2023; 44 (47) 4953-4964
• 24 Folsom AR, Lutsey PL, Heckbert SR, Cushman M. Serum albumin and risk of venous thromboembolism. Thromb Haemost 2010; 104 (01) 100-104
• 25 Huang T, An Z, Huang Z, Gao W, Hao B, Xu J. Serum albumin and cardiovascular disease: a Mendelian randomization study. BMC Cardiovasc Disord 2024; 24 (01) 196
• 26 Djoussé L, Rothman KJ, Cupples LA, Levy D, Ellison RC. Serum albumin and risk of myocardial infarction and all-cause mortality in the Framingham Offspring Study. Circulation 2002; 106 (23) 2919-2924